These trials have investigated a wide range of PI3K/AKT inhibitors as monotherapy or in combination with other anticancer agents across different cancer types, including breast cancer, colorectal cancer, lung cancer, and melanoma. The gene discussed is AKT1; the disease is colorectal cancer.